CN105651848A - Protective-agent-containing capillary gel electrophoresis detection kit - Google Patents
Protective-agent-containing capillary gel electrophoresis detection kit Download PDFInfo
- Publication number
- CN105651848A CN105651848A CN201410640495.4A CN201410640495A CN105651848A CN 105651848 A CN105651848 A CN 105651848A CN 201410640495 A CN201410640495 A CN 201410640495A CN 105651848 A CN105651848 A CN 105651848A
- Authority
- CN
- China
- Prior art keywords
- buffer
- acid
- damping fluid
- preferable
- test kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 15
- 238000001818 capillary gel electrophoresis Methods 0.000 title claims abstract description 8
- 239000003223 protective agent Substances 0.000 title abstract 3
- 229930006000 Sucrose Natural products 0.000 claims abstract description 25
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 11
- 206010054094 Tumour necrosis Diseases 0.000 claims abstract description 9
- 150000001413 amino acids Chemical class 0.000 claims abstract description 8
- 229940100601 interleukin-6 Drugs 0.000 claims abstract description 4
- 229960001612 trastuzumab emtansine Drugs 0.000 claims abstract description 4
- 239000012723 sample buffer Substances 0.000 claims description 25
- 239000005720 sucrose Substances 0.000 claims description 24
- 238000013016 damping Methods 0.000 claims description 23
- 239000012530 fluid Substances 0.000 claims description 23
- 238000012360 testing method Methods 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 16
- 230000001681 protective effect Effects 0.000 claims description 16
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 claims description 14
- 239000000872 buffer Substances 0.000 claims description 12
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 10
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229940024606 amino acid Drugs 0.000 claims description 7
- 235000001014 amino acid Nutrition 0.000 claims description 7
- 230000000259 anti-tumor effect Effects 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000007983 Tris buffer Substances 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 239000006035 Tryptophane Substances 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 229940072107 ascorbate Drugs 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 238000005336 cracking Methods 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 229960002989 glutamic acid Drugs 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- -1 polyoxyethylene Polymers 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000008362 succinate buffer Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 229960004799 tryptophan Drugs 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 238000013368 capillary electrophoresis sodium dodecyl sulfate analysis Methods 0.000 claims 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims 1
- 238000005251 capillar electrophoresis Methods 0.000 abstract description 7
- 229960000074 biopharmaceutical Drugs 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 229920005862 polyol Polymers 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 6
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 101100075829 Caenorhabditis elegans mab-3 gene Proteins 0.000 description 1
- 101100075830 Caenorhabditis elegans mab-5 gene Proteins 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to a protective-agent-containing capillary gel electrophoresis detection kit, a protective agent is selected from white sugar, a polyol or an amino acid. The kit can improve the accuracy of capillary electrophoresis detection of the purity of biopharmaceuticals such as antibodies, reduces the detection deviation generated in an actual experimental operation process and can better reflect actual contents of various isomers, especially debris, of antibody molecules contained in a sample itself, and antibodies include recombinant anti-HER2 humanized monoclonal antibodies, recombinant human-mouse chimeric anti-tumor-necrosis-factor-alpha monoclonal antibodies, recombinant anti-interleukin-6 receptor humanized monoclonal antibodies, T-DM1, recombinant anti-tumor-necrosis-factor-alpha fully-humanized monoclonal antibody injections and recombinant anti-CD52 humanized monoclonal antibodies.
Description
Technical field
The invention belongs to biological technical field, particularly relate to and a kind of can accurately detect bio-pharmaceuticals such as the capillary gel electrophoresis detection kit of antibody purity.
Background technology
Capillary electrophoresis (capillaryelectrophoresis, CE) technology is developed by conventional gel electrophoresis (gelelectrophoresis), it is taking the highfield of high voltage electric generation as motivating force, taking the quartz capillary of microbore as split tunnel. compare traditional gel electrophoresis, CE have automatization, fast, the accurate advantage such as quantitative, high resolving power, a lot of biomolecules, such as protein, polysaccharide and nucleic acid etc. can use capillary electrophoresis to analyze. sodium laurylsulfonate capillary electrophoresis (CE-SDS) technology adds linear gel in kapillary dissociating buffer to form molecular sieve, add anion surfactant sodium laurylsulfonate (sodiumdodecylsulfate, SDS) damping fluid to sample makes protein denaturation, and with protein is combined by the mass ratio of 1: 1.4, owing to this kind of protein-bonded mass-to-charge ratio of SDS is identical, the electrical forces that this associated proteins is subject to when carrying out kapillary and be separated is also identical, but owing to the size of differing molecular is different, thus in linear gel molecular sieves, the resistance size being subject to is moved different, make rate of migration different, thus the molecule realizing apparent upper molecular weight different is separated. non-reduced type CE-SDS iodo-acid amide processes, main different fragments, weight chain and the covalently bound polymer impurity detected in monoclonal antibody sample.
U.S.'s Beckman company PA800+ type capillary electrophoresis apparatus and supporting detection kit contain following component: sample buffer (samplebuffer), gel buffer liquid (gelbuffer), scavenging solution (0.1MNaOH, 0.1MHCl), interior mark (interstandard), reference standards (controlstandard), wherein sample buffer (samplebuffer) is containing 100mMTris-HCl, 1%SDS and 12.5mM iodo-acid amide. we use the sample buffer in this test kit the anti-HER 2 humanized monoclonal antibody of restructuring (mAbl) carried out the different structure of non-reduced type CE-SDS molecular size analyze time, find under the testing conditions (70 DEG C are heated 10 minutes) of Beckman manufacturer's recommended, the shive content (as containing a light chain of antibody L and the fragment containing heavy chain of antibody-heavy chain-light chain HHL) obtained is (see Fig. 1, CE-SDS main peak content 89.5%, shive content 10.5%) obviously higher than the content using additive method to obtain such as size exclusive chromatography (SEC-HPLC) (see Fig. 2, SEC-HPLC main peak content > 99%, shive content < 0.5%).By document (the .Suppressionofsodiumdodecylsulfate-polyacrylamidegelelec trophoresissamplepreparationaritfactsforanalysisofIgG4ha lf-antibodies.AnalyticalBiochemistry such as TaylorFR, 2006,353,204-208.) and our data analysis, these fragment impurity increased may be combines due to antibody and SDS and carry out the degraded product of formation in heat-treatment process. The iodo-acid amide of manufacturer's recommended is used can obviously to reduce shive content as inhibitor; but shive content is still obviously higher (as antibody mAbl purity made containing 12.5mM iodo-acid amide to be increased to 89.5% from 81% as protective material, but continue to increase iodo-acid amide concentration and purity can only be made to be increased to 90.6% to 37.5mM). Therefore, how to find a kind of formation that can obviously reduce fragment, thus to improve bio-pharmaceuticals such as the method for antibody test accuracy be problem demanding prompt solution.
Such as, it has been found that containing, on the basis of iodo-acid amide, the protective material adding other types can also improve antibody further, the CE-SDS of mAbl detects purity, namely can more accurately reflect the quality of antibody drug, thus complete the present invention.
Summary of the invention
The actual technical problem to be solved of the present invention; it it is exactly the deficiency for existing non-reduced type CE-SDS detection method; providing a kind of containing protectant capillary gel electrophoresis detection kit, this test kit can improve the accuracy that non-reduced type CE-SDS detects antibody molecule size isomer.
The technical solution used in the present invention is:
A kind of capillary gel electrophoresis detection kit containing sample buffer; containing a kind of protective material in described sample buffer (samplebuffer); described protective material concentration is 10-5000mM, it is preferable to 100-2000mM, it is more preferable to 500-1000mM.
Wherein, protective material of the present invention can suppress biological medicament if monoclonal antibody owing to occurring degraded to form fragment (fragmentation) in sample handling processes, and this protective material is selected from sugar, polyvalent alcohol or amino acid. In the present invention, amino acid is the wide in range implication of this area, comprises the form of its pharmacologically acceptable salt. Wherein, described sugar can be selected from fructose, glucose, sucrose, trehalose, seminose, lactose, maltose, sorbose, dextran, dextrin, cyclodextrin, hydroxyethylamyle or its combination, it is preferable that glucose, sucrose, trehalose or seminose. Described polyvalent alcohol can be selected from N.F,USP MANNITOL, glycerine, sorbyl alcohol, Saccharum lactis, maltose alcohol, Xylitol, propylene glycol, polyoxyethylene glycol or its combination, it is preferable that N.F,USP MANNITOL. Amino acid can be selected from L-Ala, arginine, l-asparagine, aspartic acid, halfcystine, glutamine, L-glutamic acid, glycine, Histidine, Isoleucine, leucine, Methionin, methionine(Met), phenylalanine, proline(Pro), Serine, Threonine, tryptophane, tyrosine, ��-amino-isovaleric acid or its combination.
Wherein, sample buffer of the present invention is further containing damping fluid, described damping fluid is selected from Tris damping fluid, phosphoric acid buffer, acetate buffer, succinate buffer, grape acid buffer, citrate buffer solution, ascorbate buffer, tartaric acid buffer, maleic acid damping fluid, lactic acid buffer, carbonic acid buffer, phenylformic acid damping fluid, imidazole buffer or buffered with amino acid liquid, preferred Tris damping fluid, it is more preferable to Tris-HCl damping fluid.The content of this damping fluid makes the pH value of described sample buffer between 3.0-10.0.
Wherein, sample buffer of the present invention is further containing sodium laurylsulfonate (SDS), and its content is between 0.1-5% (w/w), it is preferable that 0.5-2% (w/w), it is more preferable to 1% (w/w).
Wherein, test kit of the present invention is further containing iodo-acid amide, and its content is between 1-200mM, it is preferable that between 5-50mM, it is more preferable to 10-30mM. Wherein other components in iodo-acid amide and test kit separately store separately, it may also be useful to front configure mixing.
Preferably, the sample buffer in test kit of the present invention is containing, for example lower component:
(1) Tris-HCl damping fluid 100mM
(2) sodium laurylsulfonate (SDS) 1% (w/w)
(3) glucose or sucrose or trehalose or N.F,USP MANNITOL 500mM
PH value is 9.0.
Invention further provides the preparation method of sample buffer as above; comprise: by the damping fluid of recipe quantity, it is preferable that Tris damping fluid, the sodium laurylsulfonate of recipe quantity and the protective material of recipe quantity; preferred glucose; sucrose, trehalose or N.F,USP MANNITOL, be dissolved in appropriate deionized water; with salt acid for adjusting pH value to 3.0-10.0; preferably 9.0, then it is settled to 500mL with deionized water, obtains sample buffer. During use, the iodo-acid amide of recipe quantity is dissolved in deionized water, it is mixed with the iodo-acid amide solution of 250mM, then testing sample sample buffer is diluted to 1mg/ml, mix according to the ratio of 95 �� L: 5 �� L with iodo-acid amide solution again, carry out the purity detecting of the non-reduced type CE-SDS of antibody molecule size isomer afterwards again.
Invention further provides test kit as above when antagonist molecule carries out non-reduced type CE-SDS detection, suppress the purposes in antibody molecule cracking, wherein, described antibody molecule is preferably recombinated anti-HER 2 humanized monoclonal antibody, the chimeric anti-TNF-�� monoclonal antibody of recombinant human mouse, anti-interleukin-6 acceptor Humanized monoclonal antibodies of recombinating, T-DM1, restructuring anti-tumor necrosis factor-�� total man's resource monoclonal antibody or anti-CD52 Humanized monoclonal antibodies of recombinating, it is more preferable to be anti-HER 2 humanized monoclonal antibody of recombinating.
The useful effect of the present invention is:
Use the present invention with the addition of protectant capillary gel electrophoresis detection kit; according to the sample treatment (70 DEG C are heated 10 minutes) that Beckman company of CE manufacturer is recommended; capillary electrophoresis detection bio-pharmaceuticals can be improved such as the accuracy of antibody purity; reduce the detection error owing to experimental implementation process produces, more can reflect the actual content of antibody molecule size isomer that sample itself contains particularly fragment.
Accompanying drawing explanation
Fig. 1 does not add the non-reduced type CE-SDS collection of illustrative plates of the anti-HER 2 humanized monoclonal antibody of protectant restructuring (mAb1)
Fig. 2 recombinates the SEC-HPLC collection of illustrative plates of anti-HER 2 humanized monoclonal antibody (mAb1)
In Fig. 3 embodiment 2, dissimilar protective material is on the non-reduced type CE-SDS purity impact of the anti-HER 2 humanized monoclonal antibody of restructuring (mAb1)
In Fig. 4 embodiment 3, dissimilar protective material is on the non-reduced type CE-SDS purity impact of restructuring anti-tumor necrosis factor-�� people's mouse chimeric mAb (mAb2)
In Fig. 5 embodiment 4, different sucrose is on the non-reduced type CE-SDS purity impact of the anti-HER 2 humanized monoclonal antibody of restructuring (mAb1)
In Fig. 6 embodiment 5, sucrose is on the non-reduced type CE-SDS purity impact of different monoclonal antibody or antibody-small molecules conjugate
Embodiment
Below by way of specific embodiment, the present invention is described further.It must be noted that following examples are for illustration of the present invention, instead of limitation of the present invention.
The non-reduced type CE-SDS purity detecting of antibody in following embodiment all uses the method that Beckman company recommends.
The preparation of embodiment 1 one typical agents boxes
Take Tris6.06g, SDS5.0g, sucrose 75g, with 420mL deionized water dissolving to clear, then with 3M salt acid for adjusting pH to 9.0, then it is settled to 500mL with deionized water, obtains sample buffer.
The iodo-acid amide of 46mg is dissolved in 1mL deionized water, is mixed with the iodo-acid amide solution of 250mM.
By recombinating, anti-HER 2 humanized monoclonal antibody (mAb1) is diluted to 1mg/mL with the above-mentioned sample buffer prepared, then mixes in the ratio of 95 �� L: 5 �� L with the above-mentioned iodo-acid amide solution prepared.
The dissimilar protective material of embodiment 2 is on the non-reduced type CE-SDS purity impact of the anti-HER 2 humanized monoclonal antibody of restructuring (mAb1)
Compare dissimilar protective material to the impact of the non-reduced type CE-SDS purity of the anti-HER 2 humanized monoclonal antibody of restructuring (mAb1). The results are shown in Table 1 and Fig. 3. Wherein, the effect of sucrose and trehalose is best, and CE-SDS purity is increased to 92.1% from 89.5%; The effect of N.F,USP MANNITOL is taken second place, and purity is 91.6%; And the effect of glycine is worst, it is only 89.7%.
Table 1. is containing different protectant reagent constituents and on restructuring anti-HER 2 humanized monoclonal antibody (mAb1) CE-SDS main peak content impact
Note: #1 is the test kit of Beckman company, and all the other are for the addition of all kinds of protectant test kit on this basis, and various protectant concentration is 500mM.
The dissimilar protective material of embodiment 3 is on the non-reduced type CE-SDS purity impact of restructuring anti-tumor necrosis factor-�� people's mouse chimeric mAb (mAb2)
Compare dissimilar protective material to the impact of the non-reduced type CE-SDS purity of restructuring anti-tumor necrosis factor-�� people's mouse chimeric mAb (mAb2). The results are shown in Table 2 and Fig. 4. Wherein, glucose, trehalose and sucrose effect are best, and CE-SDS purity is increased to 91.6%, 91.3% and 91.0% respectively from 88.9%; The effect of sorbyl alcohol, glycine and N.F,USP MANNITOL is taken second place, and purity is respectively 90.2%, 90.2% and 90.0%; And the effect of glycerine is worst, it is only 89.1%.
Table 2. is containing different protectant reagent constituents and on restructuring anti-tumor necrosis factor-�� people's mouse chimeric mAb (mAb2) CE-SDS main peak content impact
Note: #6 is the test kit of Beckman company, and all the other are for the addition of all kinds of protectant test kit on this basis, and various protectant concentration is 500mM.
Embodiment 4 different sucrose is on the non-reduced type CE-SDS purity impact of the anti-HER 2 humanized monoclonal antibody of restructuring (mAb1)
The sucrose comparing different concns, on the impact of the purity of the non-reduced type CE-SDS of the anti-HER 2 humanized monoclonal antibody of restructuring (mAb1), the results are shown in Table 3 and Fig. 5. In sensing range (146-1020mM), the protected effect of sucrose and its concentration are directly related, and concentration is more high, and protected effect is more obvious.
The reagent component of table 3. containing different sucrose is to the CE-SDS main peak content balance of the anti-HER 2 humanized monoclonal antibody of restructuring (mAb1)
| # | Sucrose concentration (mM) | Non-reduced type CE-SDS main peak (%) |
| 1 | 0 | 89.5 |
| 14 | 146 | 91.3 |
| 15 | 292 | 91.6 |
| 16 | 439 | 91.8 |
| 17 | 731 | 92.0 |
| 18 | 877 | 92.2 |
| 19 | 1020 | 92.5 |
Embodiment 5 sucrose (500mM) is on the non-reduced type CE-SDS purity impact of different monoclonal antibody
Compare sucrose (500mM) to different monoclonal antibody or antibody-small molecules conjugate, comprise the impact of the non-reduced type CE-SDS purity of the anti-HER 2 humanized monoclonal antibody of restructuring (mAb1), the chimeric anti-TNF-�� monoclonal antibody (mAb2) of recombinant human mouse, anti-interleukin-6 acceptor Humanized monoclonal antibodies (mAb3) of recombinating, T-DM1 (mAb4), restructuring anti-tumor necrosis factor-�� total man's resource monoclonal antibody injection liquid (mAb5) and the anti-CD52 Humanized monoclonal antibodies (mAb6) of restructuring.The results are shown in Table 4 and Fig. 6. Due to the difference of antibody character, the stability shown in CE-SDS sample use process is different, and the protected effect of sucrose is also different. The protected effect that generally speaking more stable antibody (such as mAb5-mAb6) sucrose itself embodies is less, and the provide protection of the antibody of less stable (such as mAb1-mAb4) sucrose own is just clearly (main peak purity difference is 2.5-3.6%).
Table 4. sucrose (500mM) is on the impact of different monoclonal antibody or the non-reduced type CE-SDS main peak purity of antibody-small molecules conjugate
Claims (10)
1. one kind contains the capillary gel electrophoresis detection kit of sample buffer, it is characterised in that, containing a kind of protective material in described sample buffer.
2. test kit according to claim 1, it is characterised in that, described protectant concentration is 10-5000mM, it is preferable to 100-2000mM, it is more preferable to 500-1000mM.
3. test kit according to claim 1 and 2, it is characterised in that, described protective material is selected from sugar, polyvalent alcohol or amino acid.
4. test kit according to claim 3, it is characterized in that, described sugar is selected from fructose, glucose, sucrose, trehalose, seminose, lactose, maltose, sorbose, dextran, dextrin, cyclodextrin, hydroxyethylamyle or its combination, it is preferable to glucose, sucrose, trehalose or seminose; Described polyvalent alcohol is selected from N.F,USP MANNITOL, glycerine, sorbyl alcohol, Saccharum lactis, maltose alcohol, Xylitol, propylene glycol, polyoxyethylene glycol or its combination, it is preferable that N.F,USP MANNITOL; Described amino acid is selected from L-Ala, arginine, l-asparagine, aspartic acid, halfcystine, glutamine, L-glutamic acid, glycine, Histidine, Isoleucine, leucine, Methionin, methionine(Met), phenylalanine, proline(Pro), Serine, Threonine, tryptophane, tyrosine, ��-amino-isovaleric acid or its combination.
5. test kit according to the arbitrary item of claim 1-4, it is characterized in that, described sample buffer is further containing damping fluid, preferably, described damping fluid is selected from Tris damping fluid, phosphoric acid buffer, acetate buffer, succinate buffer, grape acid buffer, citrate buffer solution, ascorbate buffer, tartaric acid buffer, maleic acid damping fluid, lactic acid buffer, carbonic acid buffer, phenylformic acid damping fluid, imidazole buffer or buffered with amino acid liquid, preferred Tris damping fluid, more preferably Tris-HCl damping fluid, the content of described damping fluid makes the pH value of described sample buffer between 3.0-10.0.
6. test kit according to the arbitrary item of claim 1-5, it is characterized in that, described sample buffer is further containing sodium laurylsulfonate, and its content is between 0.1-5% (w/w), preferred 0.5-2% (w/w), it is more preferable to 1% (w/w).
7. test kit according to the arbitrary item of claim 1-6, it is characterised in that, described test kit is further containing iodo-acid amide, and its content is between 1-200mM, it is preferable that between 5-50mM, it is more preferable to 10-30mM.
8. test kit according to the arbitrary item of claim 1-7, it is characterised in that, described sample buffer is containing, for example lower component:
(1) Tris-HCl damping fluid 100mM
(2) sodium laurylsulfonate 1% (w/w)
(3) glucose or sucrose or trehalose or N.F,USP MANNITOL 500mM
PH value is 9.0.
9. prepare the method for the sample buffer in the claim 1-8 described test kit of arbitrary item for one kind, it is characterised in that, described method comprises:
By the damping fluid of recipe quantity; preferred Tris damping fluid; the sodium laurylsulfonate of recipe quantity and the protective material of recipe quantity, it is preferable that glucose, sucrose; trehalose or N.F,USP MANNITOL; it is dissolved in appropriate deionized water, with salt acid for adjusting pH value to 3.0-10.0, it is preferable that 9.0; then it is settled to 500mL with deionized water, obtains sample buffer.
10. test kit described in the arbitrary item of claim 1-8 antagonist molecule carry out non-reduced type CE-SDS detect time, suppress the purposes in antibody molecule cracking, wherein, described antibody molecule is preferably recombinated anti-HER 2 humanized monoclonal antibody, the chimeric anti-TNF-�� monoclonal antibody of recombinant human mouse, anti-interleukin-6 acceptor Humanized monoclonal antibodies of recombinating, T-DM1, restructuring anti-tumor necrosis factor-�� total man's resource monoclonal antibody or anti-CD52 Humanized monoclonal antibodies of recombinating, it is more preferable to be anti-HER 2 humanized monoclonal antibody of recombinating.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410640495.4A CN105651848A (en) | 2014-11-13 | 2014-11-13 | Protective-agent-containing capillary gel electrophoresis detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410640495.4A CN105651848A (en) | 2014-11-13 | 2014-11-13 | Protective-agent-containing capillary gel electrophoresis detection kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105651848A true CN105651848A (en) | 2016-06-08 |
Family
ID=56479476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410640495.4A Pending CN105651848A (en) | 2014-11-13 | 2014-11-13 | Protective-agent-containing capillary gel electrophoresis detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105651848A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113189184A (en) * | 2021-04-28 | 2021-07-30 | 浙江大学 | Capillary gel electrophoresis sample buffer solution containing cysteine |
| CN118348098A (en) * | 2024-03-31 | 2024-07-16 | 珠海联邦生物医药有限公司 | A gel separation buffer for capillary electrophoresis detection |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1503906A (en) * | 2000-09-25 | 2004-06-09 | �����ɷ� | High speed, high resolution compositions, methods and kits for capillary electrophoresis |
| CN102686241A (en) * | 2009-12-29 | 2012-09-19 | 霍夫曼-拉罗奇有限公司 | Antibody formulation |
-
2014
- 2014-11-13 CN CN201410640495.4A patent/CN105651848A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1503906A (en) * | 2000-09-25 | 2004-06-09 | �����ɷ� | High speed, high resolution compositions, methods and kits for capillary electrophoresis |
| CN104132992A (en) * | 2000-09-25 | 2014-11-05 | 应用生物系统有限公司 | High speed, high resolution compositions, methods, and kits for capillary electrophoresis |
| CN102686241A (en) * | 2009-12-29 | 2012-09-19 | 霍夫曼-拉罗奇有限公司 | Antibody formulation |
Non-Patent Citations (2)
| Title |
|---|
| BECKMAN COULTER, INC.: "《Application Guide》", 28 February 2011 * |
| RICHARD R. RUSTANDI ET.AL.: "Applications of CE SDS gel in development of biopharmaceutical antibody-based products", 《ELECTROPHORESIS》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113189184A (en) * | 2021-04-28 | 2021-07-30 | 浙江大学 | Capillary gel electrophoresis sample buffer solution containing cysteine |
| CN113189184B (en) * | 2021-04-28 | 2022-09-09 | 浙江大学 | Capillary gel electrophoresis sample buffer containing cysteine |
| WO2022227363A1 (en) * | 2021-04-28 | 2022-11-03 | 浙江大学 | Capillary gel electrophoresis sample buffer containing cysteine |
| CN118348098A (en) * | 2024-03-31 | 2024-07-16 | 珠海联邦生物医药有限公司 | A gel separation buffer for capillary electrophoresis detection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chollangi et al. | Development of robust antibody purification by optimizing protein‐A chromatography in combination with precipitation methodologies | |
| ES2869396T3 (en) | Purification of Recombinantly Produced Polypeptides | |
| Tian et al. | Small-angle x-ray scattering screening complements conventional biophysical analysis: comparative structural and biophysical analysis of monoclonal antibodies IgG1, IgG2, and IgG4 | |
| Singh et al. | Effect of polysorbate 80 quality on photostability of a monoclonal antibody | |
| US12030948B2 (en) | Antibody formulation | |
| US10330650B2 (en) | High performance liquid chromatography method for polypeptide mixtures | |
| FI3408295T3 (en) | Pharmaceutical composition comprising bispecific antibody constructs | |
| US12433947B2 (en) | Stable formulations of therapeutic antibody | |
| EA012162B1 (en) | Methods for refolding of recombinant antibodies | |
| CN110831621A (en) | Stable liquid pharmaceutical composition | |
| WO2021009669A2 (en) | A process for separation and quantitation of proteins using capillary electrophoresis | |
| Hinterholzer et al. | Detecting aspartate isomerization and backbone cleavage after aspartate in intact proteins by NMR spectroscopy | |
| Stackhouse et al. | A high‐throughput UPLC method for the characterization of chemical modifications in monoclonal antibody molecules | |
| CN105651848A (en) | Protective-agent-containing capillary gel electrophoresis detection kit | |
| Xu et al. | Interrogating heterogeneity of cysteine-engineered antibody-drug conjugates and antibody-oligonucleotide conjugates by capillary zone electrophoresis-mass spectrometry | |
| Chang et al. | Physical stability of protein pharmaceuticals | |
| Hu et al. | Sodium caprylate wash during Protein A chromatography as an effective means for removing protease (s) responsible for target antibody fragmentation | |
| Yamada et al. | Combination of SDS‐PAGE and intact mass analysis for rapid determination of heterogeneities in monoclonal antibody therapeutics | |
| WO2023073469A1 (en) | STABLE LYOPHILIZED FORMULATION OF AN ANTI-α4ß7 ANTIBODY | |
| Aono et al. | Efficient on-column conversion of IgG1 trisulfide linkages to native disulfides in tandem with Protein A affinity chromatography | |
| US10023609B2 (en) | Methods for reducing chromatin content in protein preparations by treatment with alkyl cations | |
| KR20240134320A (en) | Reduced polysorbate degradation in protein preparations by small amounts of citric acid | |
| US20210253714A1 (en) | Stable antibody formulation | |
| JP2022531331A (en) | Anti-IL-6 antibody preparation | |
| CN118961852A (en) | Gel buffers and methods for capillary electrophoresis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190523 Address after: 318000 No. 1 Shugang Avenue, Jiaojiang District, Taizhou City, Zhejiang Province Applicant after: Zhejiang Haizheng Borui Biopharmaceutical Co., Ltd. Address before: No. 46, Jiaojiang District, Taizhou, Zhejiang Province Applicant before: Zhejiang Hisun Pharmaceutical Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160608 |
|
| RJ01 | Rejection of invention patent application after publication |